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Background: OSAS and COPD are often associated with day-time hypoxemia. Overlap Syndrome
(OS), the association between both diseases, increases the risk of day-time hypoxemia. The
aim of this study was to investigate the mechanisms which could justify the low oxygen level
and the effect of CPAP.
Methods: We performed a retrospective analysis in all patients referred to our institutes for
suspected OSAS and who also underwent spirometry and blood gas analysis during our evalu-
ation. Thus, 720 patients were selected. According to pulmonary function test parameters they
were divided into 3 groups: OSAS (NZ 466,65%); OS (NZ 168,23%) and COPD (NZ 86,12%). In
order to evaluate the differences between the three groups, ANOVA analyses were carried out,
whereas a multivariate analysis was performed in order to evaluate which factors determine
the diurnal PaO2. In 90 patients we also have the data on blood gas analysis after one year
of CPAP treatment, so we evaluate the PaO2 improvement in accordance with compliance to
treatment in these patient subgroups.
Results: The OS group showed a lower level of daytime PaO2 compared with OSAS patients and
T90 was higher in OS compared with OSAS. A multivariate analysis showed that in the OS diurnal
PaO2 correlated with age (bZ 0.20) and moreover with FEV1 (bZ 0.31) and T90 (bZ 0.37),
while in the OSAS a correlation was found with FEV1 (b Z 0.11) and mostly with BMI
(bZ 0.25), age and T90. In all patients with good compliance to CPAP day-time PaO2 improved.
Conclusions: Our data suggest that day-time hypoxemia in OSA patients is largely determined by
the increase of body weight and severity of nocturnal hypoxia. However, CPAP therapy has been
shown to improve daytime PaO2 values both in OSAS and in OS.
ª 2012 Elsevier Ltd. All rights reserved.382592807; fax: þ39 0382592024.
@fsm.it (F. Fanfulla).
2 Elsevier Ltd. All rights reserved.
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evaluatedwhile flow, snoring, sleep position, legmovements,Obstructive Sleep Apnea (OSAS) is the most frequent sleep-
related breathing disorder and has a significant impact on
nocturnal arterial oxygenation1 but also on development of
daytime hypoxemia.2 The presence of sleep oxyhemoglobin
desaturation has been recognized as a risk factor for
developing pulmonary arterial hypertension, above all in
patients affected by OSAS in conjunction with COPD. The
coexistence of COPD and OSAS, known as Overlap Syndrome
(OS), amounts to about 1% of adult males, and is known to
increase the risk of systemic inflammation and cardiovas-
cular diseases.3,4 In these patients the severity of nocturnal
desaturation is higher than in patients affected by OSAS or
COPD alone. Moreover, patients who have nocturnal hypox-
emia often present a low level of PaO2 during wakefulness,
although the relationship between nocturnal desaturation
and day-time PaO2 is not well understood. However, what is
known is that in COPD hypoxemia is associated with
a reduction of quality of life, low-exercise tolerance, and
increased risk of death5 The treatment of severe hypoxemia
with long-term oxygen therapy (LTOT) remains the only
intervention that can be useful in hypoxemic COPD, while
the role of nocturnal ventilation is still debated. Sleep has
significant effects on respiration in healthy subjects and
even in patients affected by pulmonary disease or sleep-
disordered breathing. The reduction of ventilation due to
a decrease of chemoreceptor sensitivity, muscle activity
reduction and alveolar hypoventilation is well documented
both in healthy subjects6 and in patients with COPD,7,8 but
few large-scale studies are available in order to investigate
the relevance of obesity, sleep-disordered breathing and
lung function on diurnal PaO2 in patients affected by OS.
The aim of this study is to increase the knowledge of
mechanismswhich link the PaO2 inwakefulness and in sleep in
a population of OSAS, COPD and OS patients, but also to verify
the impact of nocturnal ventilation in patients with sleep
disorder breathing on the improvement of diurnal PaO2.
Materials and methods
We performed a retrospective analysis on the subset of
subjects who referred to the sleep laboratories of University
of Foggia and Fondazione Maugeri, Cassano Murge (Bari) from
2007 to 2011 for suspected OSAS and who in addition to
nocturnal cardio-respiratory polygraphy, according to
a physician’s evaluation, also underwent spirometry, blood
gas analysis and the6-minwalking test.Patientswith central
apnea, heart failure, Obesity Hypoventilation Syndrome, and
other chronic pulmonary diseases such as fibrosis or neuro-
muscular diseases were not included in the study.
In accordance with the results of nocturnal polygraphy
and pulmonary function tests the subjects were divided
into three groups: OSASþ/COPD- (OSAS); OSASþ/COPDþ
(OS); OSAS /COPDþ (COPD). The study was approved by
the institutional ethics committee.
Polygraphy
Unattended cardio-respiratory overnight monitoring (Vital-
night 11, Germany) was performed during the patient’shospital stay in the sleep laboratory. Sleep stages were not
SaO2 and heart rate were recorded. Oro-nasal flow was
measuredbyanasal cannula,whereas abdominal and rib-cage
movements were measured by pneumatic sensors and
oxyhemoglobin saturation with a finger probe. Sleep-
disordered breathing was quantified according to standard
criteria,9 in summary: obstructive apnea was defined as
a reduction of the flow at 90%, lasting at least for 10 s with the
presence of abdominal or thoracic movement, central apnea
in absence of both. Hypopnea was identified when there was
a 50% reduction of flow for 10 s or more followed by a 4%
decrease of saturation. AHI was defined as a number value
corresponding to apnea plus hypopnea divided by the hours of
registration, Oxygendesaturation index (ODI) was the number
of desaturation>4% divided by the hours of registration. The
exam was considered to be valid if there were at least 6 h of
registration. A manual score was performed the day after
registration by two doctors (one for each center) expert in
sleep disorder, both of whom respected the same criteria.
Six-minute walking test
The 6MWT was performed in accordance with standard
guidelines10 in a corridor which was 20 m long; meter-by-
meter marks were made and two cones signaled the walk
turn. Parameters such as BP, HR, SpO2, and the modified
Borg scale were collected both during the early and late
phases of the walk. When the test was terminated, the
distance covered was calculated using the notes of the
number of turns performed by the patient.
Blood gas analysis and AaDO2
The arterial blood sample for the analysis of gases during
room-air breathing was drawn with the patient in a sitting
position on the day after the polygraphy registration and
within 1 h ofwaking up. PaO2, PaCO2 andpHweremeasured in
a blood gas analyzer (Model 1312; Instrumentation Labora-
tory; Milan, Italy). The alveolar-arterial difference (AaDO2)
was calculated by the equation: 150-(PaCO2/0.8)-PaO2.
Pulmonary function testing
Pulmonary function tests were performed in the pulmonary
function laboratory of our Institutes using a spirometer
(Sensormedics, USA). The equipment was calibrated daily
using a 3-L syringe. The best of three reproducible spiro-
metric values was expressed as a percentage of the pre-
dicted normal value; spirometry was repeated 15 min after
the subject had inhaled 400 mg of salbutamol. Patients with
a positive reversibility test (FEV1 post-bronchodilatator
better than 12% pre-bronchodilatator) were not included
in the study. In accordance with GOLD guidelines the
subjects were classified as COPD if FEV1/FVC was <70%.
Statistical analysis
Descriptive statistics (i.e. means, standard deviations,
percentages) were applied to summarize the continuous
312 D. Lacedonia et al.and categorical variables. The relationship between two
continuous variables was determined by measuring the
Pearson’s correlation coefficient. Overall differences
among the three groups of patients (Overlap, COPD, OSAS)
were tested by the ANOVA; the Tukey post-hoc analysis with
the Spjotvol/Stoline test for unequal sample was per-
formed to assess differences between each group. The
student’s t-test for dependent samples was used to assess
differences over time in blood gas values or BMI according
to long-term CPAP compliance. Multiple linear regression
was used, both for the total group and the three subgroups,
independently. Statistical Software (Statistica version 8.0,
StatSoft, Inc. 2007, USA), was used to analyze the data.Results
In accordance with the inclusion criteria 720 patients were
selected for analysis. 466 (65%) were affected by OSAS
without COPD (OSAS group); 86 (12%) patients were only
COPD and not OSAS (COPD group), while 168 (23%) patients
had both diseases (OS group). OSAS patients were younger
than the OS who were younger than the COPD patients. No
differences regarded BMI in OSAS vs OS but both had
a higher BMI than COPD. The COPD group had a more severe
obstructive disease than the OS ones (FEV1/FVC and FEV1
were lower in COPD than in OS). In the OS group the
percentage of sleep time with SaO2 below 90% (T90) was
higher than in the OSAS group. Interestingly, even if OS
were younger and had better pulmonary functions thanTable 1 General characteristics of patients. NC: neck circumf
received fixed CPAP after titration by autoCPAP, BiLevel was use
guidelines O2 was added if SaO2 persisted under 90% for more th
All OSAS Overla
Mean SD Mean SD Mean
N (%) 720.00 466 (65) 168 (23
Male % 73.00 70.00 77.00
Age (years) 62.05 12.69 58.18 12.32 67.68
BMI (Kg/m2) 32.49 6.79 33.52 6.60 32.57
NC (cm) 44.23 4.21 44.05 4.20 45.45
ESS 11.69 6.09 11.39 6.08 13.89
AHI (events/
hours)
43.20 22.92 43.48 23.28 42.42
ODI 4% (events/
hours)
39.45 25.14 36.94 26.79 43.90
T90 (%) 26.94 29.17 23.90 26.74 34.62
FVC (%) 91.02 18.40 95.88 16.98 80.74
FEV1 (%) 83.76 23.92 95.32 17.02 61.77
FEV1/FVC 73.23 14.67 81.20 6.87 58.47
ph 7.42 0.03 7.42 0.03 7.42
PaO2 (mmHg) 75.31 9.98 77.98 9.38 70.25
PaCO2 (mmHg) 38.86 4.19 38.30 3.48 39.86
AaDO2 28.82 17.38 28.48 20.58 29.93
SaO2 (%) 95.12 2.97 95.61 3.08 93.99
6MWT (mt) 305.11 121.76 329.64 128.99 281.75
CPAP (cmH20) 10.44 2.16 10.37 2.20 10.64
N Bi-Level (%) 13 (2) 9 (2) 4 (2)
N CPAP þ O2 (%) 114 (18) 21 (4.5) 93 (55)COPD, no differences were found regarding gas exchange
for diurnal PaO2, PaCO2, or regarding 6MWT, while these
values were lower than in OSAS patients (see Table 1 for
more details).
The correlation coefficients between age, BMI, AHI, T90,
and PaO2 for each group are shown in Table 2. The rela-
tionship between diurnal PaO2 and other parameters were
different in each group. Indeed, in OSAS patients PaO2 was
linked with Age, BMI, AHI, BMI, and FEV1, even if the higher
coefficient was to do with T90 and BMI. In patients with
COPD only the FEV1 showed a negative correlation with
diurnal PaO2. Finally in OS, as in OSAS, PaO2 was linked with
all the parameters analyzed except BMI, but the highest
coefficient was found with T90. Regarding 6MWT no
parameters were linked with it in COPD, whereas there was
a correlation with age and diurnal PaO2 in OS, while in OSAS
only age had a negative correlation.
The results were substantially confirmed by multiple
regression analysis. PaO2 in the OSAS group was strongly
related with BMI and age but less than with T90. In OS T90
and FEV1 were more important, while in COPD only FEV1
was linked with PaO2. 6MWT, on the other hand, was con-
nected with age and BMI but only in the OS group, while in
OSAS and COPD no parameters were linked with it (Table 3).
Ninety patients (55 OSAS and 35 OS) had a control visit and
a newblood gas analysis one year after baseline; thus only for
these peoplewas it possible to verifywhether nocturnal fixed
CPAP can improve gas exchange. The patients were divided
into two groups according to their referred use of CPAP, and
only when it was possible by download of information fromerence; T90: time in bed spent with SpO2 <90%. All patients
d in patients who did not tolerate CPAP. According to Italian
an 30% of registration time.
p COPD Anova
F (p)
Post-hoc analysis
SD Mean SD
) 86 (12)
86.00
10.58 72.05 8.04 <0.0001 OSAS < OS < COPD
6.97 26.81 4.21 <0.0001 OSAS Z OS > COPD
4.15 40.22 4.12 <0.0001 OSAS Z OS > COPD
5.84 4.84 2.24 <0.0001 OSAS Z OS > COPD
21.94 5.31 3.02 <0.0001 OSAS Z OS > COPD
21.33 6.63 2.37 <0.0001 OSAS > OS > COPD
33.44 4.45 2.21 <0.0001 OS > OSAS > COPD
17.40 80.06 16.29 <0.0001 OSAS > OS Z COPD
16.06 55.55 17.41 <0.0001 OSAS > OS > COPD
10.15 51.05 11.74 <0.0001 OSAS > OS > COPD
0.03 7.42 0.03 NS
10.01 71.55 7.70 <0.0001 OSAS > OS Z COPD
4.96 39.94 5.40 <0.0001 OSAS < OS Z COPD
9.43 28.52 7.97 NS
2.69 94.46 1.46 <0.0001 OSAS > OS Z COPD
116.84 286.14 101.87 <0.001 OSAS > OS Z COPD
2.04 NS
Table 2 Correlations between age, pulmonary function,
nocturnal parameters and PaO2 in each groups. In bold we
marked when correlation was statistically significant
(p < 0.01).
BMI AHI T90 FEV1 PaO2 6MWT
OSAS
Age 0.1 0.3 2.0 0.5 2.7 1.9
BMI 3.1 3.4 1.8 3.6 0.3
AHI 42 1.0 2.0 0.6
T90 1.4 3.7 1.1
FEV1 2.1 0.8
PaO2 1.0
OS
Age 1.3 0.2 0.1 1.0 2.3 4.7
BMI 3.9 2.3 0.6 0.3 2.0
AHI 31 0.6 1.5 0.6
T90 0.4 4.0 0.3
FEV1 3.4 1.5
PaO2 2.0
COPD
Age 0.7 1.4 1.2 0.7
BMI 1.1 0.9 0.3
FEV1 2.7 1.9
PaO2 1.0
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CPAP scantily were assigned to a “non-compliance” group,
while patients who reported daily machine use were classi-
fied as “good compliance”. At baseline no differences exis-
ted between the two groups as regards BMI, severity of sleep
disorder and lung function, while PaO2 was lower in the good
compliance group. After one year all the subjects with good
compliance had an improvement of diurnal PaO2 and PaCO2,
while thepatients notusingCPAP showedaworsening of PaO2
and no change in PaCO2. These results were true both for
OSAS and OS patients, even if in “no compliance” OS there
wasn’t any variation in gas exchange, although there was an
improvement in the compliance group for PaO2 and PaCO2.
Further, in “no compliance” OSAS there was a worsening
of PaO2, while daytime PaO2 improved in complianceTable 3 Results of multivariate analysis for each group
and for entire population. The table show only the results
that were statistically significant (p < 0.001).
All OSAS OS COPD
PaO2 Beta Beta Beta Beta
Age 0.22 0.22 0.20
BMI 0.11 0.25
AHI
T90 0.27 0.21 0.37
FEV1 0.28 0.11 0.31 0.27
6MWT
Age 0.27 0.19 0.49
BMI 0.26
AHI
T90
FEV1
PaO2patients, no change being observed in PaCO2. (Table 4,
Fig. 1). In patients who needed an O2 supplement during
night use of CPAP, the addition of O2 wasn’t sufficient to
improve PaO2 if the patient had no compliance with CPAP
(data not shown).Discussion
The main result of this study lies in the number of apnea
and hypopnea (AHI) per se not influencing daytime PaO2,
while a strong relevance could be due to nocturnal desa-
turation expressed as T90, which is more true in patients
with OS than in those who have only OSAS, where age and
mostly BMI seem to have a more relevant role. This study
demonstrated that many parameters can play an important
role in influencing diurnal PaO2, though it seems that the
models which can explain this relationship are different in
patients with OS than in solely OSAS (Fig. 2).
Lastly, another important result of this study is that
nocturnal use of CPAP can improve diurnal PaO2 not only in
overlap patients but also in OSAS ones.
Previous studies have shown that patients with OSAS
have a lower level of diurnal PaO2 compared with normal
subjects, but the causes of daytime hypoxemia are not
totally clear. The presence of pulmonary hypertension, by
pulmonary vasoconstriction, has been identified as the
main condition which can contribute to reducing the
oxygen level in arterial blood.11,12 In a large-scale study,
Peppard and co-workers found that BMI is the most impor-
tant predictive factor of the severity of oxygen desatura-
tion during apnea or hypopnea.13 Change in lung volume
and, in particular, the reduction of functional reserve
capacity (FRC) associated with higher body requirement of
oxygen14 could be the main mechanisms by which nocturnal
desaturation is deeper in obese patients than in lean
ones.15 Besides the increase of airway resistances16 and
reduction of lung ventilation during sleep and mostly in REM
stage,17 there is also a worsening of ventilation/perfusion
mismatching and then as regards SaO2.
One interesting result of this study is that in patients
with overlap syndrome day-time hypoxemia seems to be
due to a slightly different mechanism. Indeed, even if in OS
diurnal PaO2 is lower than in OSAS, in this case the BMI is
not correlated with diurnal PaO2, while nocturnal hypo-
ventilation is strongly correlated with low levels of PaO2.
Different mechanisms are involved in the pathogenesis
of hypoventilation during sleep in COPD patients. First of
all, during sleep there is a further reduction of FRC and an
increase of closing volume, which is associated with mucus
accumulation in the airways, worsening the ventilation/
perfusion mismatch. Moreover, in particular during REM
sleep, the abolition of intercostal and accessory muscle
activity is poorly supported by a good diaphragmatic
contraction, which is impaired in these patients,18 hence
the final result is the relevant reduction of minute venti-
lation.19 When OSAS and COPD are present together, as in
OS, the result is a deeper desaturation and a higher time
with SaO2 under 90% during sleep.
Sands and co-workers20 have shown that SaO2 desatu-
ration is deeper when repetitive apneas occur because
venous hypoxemia subsequent to apnea can fast deplete
Table 4 BMI and gas analysis before and after treatment in patients with good and bad compliance to nocturnal ventilation. In
bold the statistically significant results.
No Compliance Good Compliance
Before After p Before After p
Mean SD Mean SD Mean SD Mean SD
ALL N 37.00 53.00
BMI 32.99 7.48 32.58 7.13 0.30 33.21 6.25 33.43 6.42 0.45
PaO2 76.58 11.00 72.22 11.06 <0.001 71.24 8.54 76.29 11.01 <0.001
PaCO2 38.10 4.12 39.40 3.99 0.06 39.92 4.24 38.54 3.34 0.01
OSAS N 26.00 29.00
BMI 33.84 7.59 33.46 7.22 0.47 33.01 6.58 33.20 6.68 0.64
PaO2 78.30 10.09 74.60 11.14 0.01 74.70 6.96 80.17 9.60 <0.001
PaCO2 38.19 4.11 39.21 4.00 0.25 38.77 2.99 37.77 3.01 0.15
OS N 11.00 24.00
BMI 31.07 7.16 30.59 6.83 0.38 33.44 5.95 33.72 6.22 0.55
PaO2 72.52 12.47 66.57 8.93 0.07 67.06 8.51 71.60 10.95 0.01
PaCO2 37.90 4.33 39.85 4.12 0.06 41.30 5.10 39.47 3.54 0.04
314 D. Lacedonia et al.alveolar O2. In patients with OS, as a consequence of sleep
hypoventilation, alveolar O2 is lower, and so when apnea
occurs, it has a more pronounced effect on arterial and
venous hypoxemia with deeper desaturation.
Overlap syndrome predisposes to day-time hypercapnia
and hypoxemia independently of lung function alone,21
Moreover, COPD is frequently complicated by the devel-
opment of pulmonary hypertension,22 especially in patients
with OS in whom pulmonary hypertension is frequent23
because in this case alveolar hypoxia, one of the most
important mechanisms leading to pulmonary arterial vaso-
constriction and pulmonary hypertension,24 is usually more
pronounced. Our results confirm these observations;
moreover, even if our patients with OS have the same PaO2
and PaCO2 as patients with only COPD these ones were
older, leaner and have a worse lung function, indicating
that it is very likely that nocturnal impairment is the cause
of lower PaO2, as suggested by multivariate analysis.
Our analysis shows that there aren’t any substantial
differences as regards exercise performance, evaluated
simply by 6MWT, between OS and COPD, even though, as ex-
pected, patients with only OSAS have a better performance.Figure 1 PaO2 before and after one year CPAP treatment in
all subjects who had bad or good compliance to CPAP.Finally, recent randomized control trials show that in-
patients with COPD nocturnal non-invasive ventilation
(NIPPV) associated with pulmonary rehabilitation can
improve their quality of life and gas exchange compared to
pulmonary rehabilitation alone.25 Indeed, even if our studyFigure 2 Different relationship between age, BMI, lung
function, SDB and PaO2 in patients with OSAS, OS or COPD. The
thickness of the arrows is proportional to p-value of multivar-
iate analysis (see Table 3). According to multivariate analysis
diurnal PaO2 in OSAS is mostly related with BMI and AGE, while
nocturnal hypoventilation (expressed as T90) is more important
in OS. In patients with COPD, with any nocturnal problems,
PaO2 is related only with severity of disease evaluated by FEV1
impairment.
Daytime PaO2 in OSAS, COPD and the combination of the two (overlap syndrome) 315is differently designed, the results are in line with these
data because our patients were all on the pulmonary
rehabilitation program, though only the patients who were
compliant to nocturnal ventilation, mostly CPAP, had ob-
tained and improvement of gas exchange. The mechanism
able to explain this observation could be different,
including: reduction of pulmonary subclinical edema,
reduction of upper resistances, more lung work and
a reduction of ventilation/perfusion mismatch, better
muscle efficiency, an increase in alveolar ventilation and
then a reduction of vasoconstriction, etc. The administra-
tion of nocturnal oxygen in patients with sleep hypo-
ventilation seems to be insufficient to improve day-time
PaO2; indeed, it is still a matter of debate whether this
therapy has a positive effect on survival or not.26 Our data
show that CPAP has a more positive impact on improvement
of diurnal PaO2, independently of the addition of oxygen.
Thus we can speculate that nocturnal ventilation, both
when it is a consequence of OSAS alone and moreso when
there is an association of OSAS and COPD, should be
preferred to oxygen alone in order to improve gas exchange
and perhaps a patient’s quality of life and survival.
However, even if it might seem superfluous, it is important
to underline that only a continued use of CPAP is really
useful to obtain a good result.
A strong point of this study lies in the large number of
patients that we included in this retrospective analysis
even if some limitations must be underlined: the most
serious is that only some of the patients who were referred
to our institutes underwent spirometry and blood gas
analysis without a specific criteria and so this could
represent a bias in the selection of population; indeed, it is
for this reason that a prospective study should be done in
order to confirm our results.
In conclusion, our results seem to support the hypothesis
that diurnal PaO2 is the result of a mix of factors (BMI, T90,
FEV1) rather than being the cause of the severe nocturnal
desaturation. The mechanisms which determine the day-
time level of PaO2 seem to vary in patients with OSAS
alone with respect to those who have OSAS and COPD in
whom nocturnal hypoventilation is more pronounced and
has a great impact on diurnal PaO2. Finally, it is worth
noting that CPAP, when correctly administrated, can
improve gas exchange and have a positive effect on the life
of patients with sleep-disordered breathing.Authorship
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